Pharmaceuticals

Global Radioligand Therapy Market Overview: Trends Shaping Growth to 2029

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Radioligand Therapy Industry Expected To Reach By 2029, Starting From 2025 Levels?

The radioligand therapy market size has shown rapid expansion in recent years. It is anticipated to grow from $6.01 billion in 2024 to $6.64 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.5%. The historical growth of this market can be attributed to factors such as the rise in liquid biopsy usage, the emergence of tumor-agnostic therapies, the integration of artificial intelligence in oncology, the expanding pipeline of bispecific antibodies, and an increase in government funding for cancer research.

The radioligand therapy market size is anticipated to undergo substantial expansion over the upcoming years. Its value is projected to reach $9.77 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.2%. This expected increase during the forecast period is driven by factors such as increasing investments from major pharmaceutical companies in oncology startups, a broader application of real-world evidence, advancements in radiopharmaceutical and theranostics research, burgeoning collaborations between academia and industry, and a rise in the occurrence of rare and orphan cancers. Prominent trends for the forecast period include AI-powered radiopharmaceutical design, theranostics employing dual imaging-therapy platforms, microfluidics-based radiotracer synthesis, next-generation alpha-emitting isotopes, and personalized 3D-printed dosimetry devices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Factors And Drivers Are Influencing The Radioligand Therapy Market In 2025?

The projected rise in cancer cases is anticipated to drive expansion within the radioligand therapy market. Cancer is characterized by the unregulated proliferation of aberrant cells, which can infiltrate adjacent tissues and disseminate throughout the body. The increasing occurrence of cancer is linked to prolonged exposure to environmental contaminants, which harm DNA, interfere with cellular processes, and foster irregular cell development. Radioligand therapy addresses cancer by targeting radiation directly at tumor cells via ligands that attach to specific receptors, thereby reducing damage to healthy tissues while internally eradicating malignant cells. For instance, in January 2022, according to the American Cancer Society, a US-based cancer awareness non-profit organization, the US was projected to see an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths, reaching up to approximately 1,670 deaths on daily basis. Consequently, the growing rate of cancer diagnoses is stimulating the expansion of the radioligand therapy market.

What Are The Leading Segments Analyzed In The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Which Trends Are Impacting The Radioligand Therapy Market?

Leading companies in the radioligand therapy market are prioritizing the development of advanced solutions, including radioligand therapy facilities, to improve production efficiency and maintain consistent quality and safety measures during the manufacturing and distribution of targeted cancer treatments. These specialized centers are specifically designed to manage and deliver radioactive drugs for targeted cancer treatment, utilizing advanced imaging systems and radiation shielding, while ensuring safety through trained staff and strict operational protocols. For example, in January 2024, Novartis AG, a pharmaceutical company based in Switzerland, announced the automation of its new large-scale radioligand therapy (RLT) production facility in Indiana. This plant secured Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility stands as Novartis’s largest and most advanced site dedicated to RLT, built for efficient, time-sensitive production, and features plans for fully automated production lines, enabling substantial increases in supply to address growing patient demand in the US and Canada.

Which Major Firms Are Strengthening Their Position In The Radioligand Therapy Industry?

Major companies operating in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc., OncoSil Medical Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Radioligand Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2025, By The Business Research Company

Property Management Service Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795